SCHEMBL6980964

SCHEMBL6980964

CC(C)(C)[C@H](NS(=O)(=O)c1ccc2ccccc2c1)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 1/20 0.44
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ SLC1A3 P43003 1/20 0.43
▸ SLC1A2 P43004 1/20 0.43
▸ SLC1A1 P43005 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ACACB O00763 1/20 0.40
▸ F2 P00734 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6978976 0.86 SLC1A3 (0.49) ADAM17CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL6979815 0.78 SLC1A3 (0.60) ADAM17CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL1770561 0.76 ADAM17 (0.60) ADAM17CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL1770556 0.76 ADAM17 (0.60) ADAM17CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL5151243 0.75 BDKRB1 (0.52) —
SCHEMBL6789625 0.74 ALDH1A1 (0.51) MAPTPKMALDH1A1HTR7KAT6A
SCHEMBL1771358 0.71 SLC1A3 (0.54) ADAM17CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL65691 0.68 PARL (0.65) TSHRMAPTPKML3MBTL1ALDH1A1
SCHEMBL7272985 0.68 GABRB1 (0.44) CYP3A4CYP2C9TSHRCYP2C19MAPT
SCHEMBL6983496 0.68 MMP2 (0.55) SLC1A3SLC1A2SLC1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 — — EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 — — US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 — — EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 — — US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 — — US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 — — EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 — — EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 — — EP disclosed
Send feedback